ZLAB · Zai Lab Limited

Zai Lab's first quarter 2026 results reflect anticipated headwinds in its commercial portfolio, particularly from ZEJULA, which saw sales drop to $30.0 million from $49.5 million a year ago due to volume-based procurement for generic olaparib. VYVGART also declined slightly to $17.6 million due to NRDL pricing adjustments. However, XACDURO and NUZYRA showed strong growth, with XACDURO surging to $8.6 million from $1.1 million on expanding hospital adoption, though supply-constrained. Total revenue of $99.6 million was down 6% year-over-year, while product revenue fell 10% (12% at CER). R&D expenses increased to $65.6 million, driven by clinical trials and licensing fees, and SG&A rose to $65.1 million. Net loss widened to $51.0 million from $48.4 million. The company highlighted pipeline progress: zoci's AACR data showing 62.5% intracranial ORR in SCLC brain metastases and 38.2% ORR in epNECs, with registrational DLLEVATE trial enrollment on track for first half 2027. Collaborations with Amgen and Boehringer Ingelheim position zoci as a potential backbone therapy. ZL-1503 preclinical data supports first-in-class potential in atopic diseases, with Phase 1/1b data expected in second half 2026. Near-term commercial catalysts include KarXT launch in China in Q2 2026, TIVDAK potential approval this year, and positive Phase 3 readouts for povetacicept and elegrobart. Cash position remains strong at $761.3 million.